MCM
XERS icon

MAI Capital Management’s Xeris Biopharma Holdings XERS Stock Holding History

MAI Capital Management’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,995
Closed -$11.6K – 4746
2026
Q1 		$11.6K Buy
1,995
+1,968
+7,289% +$13K ﹤0.01% 3097
2025
Q4 		$212 Buy
+27
New +$212 ﹤0.01% 4030

Other funds holding XERS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $269M AUM 103.38% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

MAI Capital Management's XERS Position: Q2 2026 in Review

MAI Capital Management sold out of Xeris Biopharma Holdings (XERS) in Q2 2026, closing a stake of 1,995 shares — an estimated $11.6K sold.

MAI Capital Management first reported a position in XERS in Q4 2025 and held it in 2 quarters. The position peaked at $11.6K in Q1 2026. 240 funds tracked by Wall St. Rank hold XERS as of Q2 2026.

  • MAI Capital Management reported no remaining Xeris Biopharma Holdings position as of Q2 2026 after selling out during the quarter.
  • MAI Capital Management sold 1,995 Xeris Biopharma Holdings shares in Q2 2026, an estimated $11.6K.
  • MAI Capital Management first reported a position in Xeris Biopharma Holdings in Q4 2025 and held it in 2 quarters.
  • MAI Capital Management's Xeris Biopharma Holdings position peaked at $11.6K in Q1 2026.
  • 240 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q2 2026.

Based on MAI Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.